Serlopitant Not Statistically Significantly Better Than Placebo in Prurigo Nodularis Studies
Menlo Therapeutics announced topline results from two phase 3 studies of serlopitant for the treatment of pruritus associated with prurigo nodularis.
Pruritus And Dry Skin
Tradipitant Misses Primary End Point in Atopic Dermatitis Trial
Vanda Pharmaceuticals announced data from the phase 3 EPIONE study of tradipitant for the treatment of pruritus in atopic dermatitis. The 8-week, multicenter, double-blind, placebo-controlled study evaluated the efficacy of tradipitant, a neurokinin-1 receptor antagonist, in 341 adult patients with atopic dermatitis who presented with severe pruritus. Patients were randomized 1:1 to receive either tradipitant…
Nemolizumab Gets Breakthrough Therapy Status for Prurigo Nodularis
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to nemolizumab (Galderma) for the treatment of pruritus associated with prurigo nodularis. Prurigo nodularis is a rare skin disease that is characterized by the formation of hard, itchy nodules on the skin. It is commonly associated with intense itching that may lead to severe…
Positive Results for Korsuva in Chronic Kidney Disease-Associated Pruritus Trial
The KALM-1 trial was a multicenter, double-blind, placebo-controlled 12-week study with a 52-week open label extension phase that evaluated the safety and efficacy of Korsuva injection in 350 hemodialysis patients
Baricitinib Beneficial in Two Phase 3 Atopic Dermatitis Trials
Lilly and Incyte announced positive top-line results from two Phase 3 clinical trials evaluating baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis. Results from the BREEZE-AD1 and BREEZE-AD2 placebo-controlled trials showed that treatment with baricitinib monotherapy led to a statistically significant proportion of patients achieving Investigator’s Global Assessment for Atopic Dermatitis score of clear…
Guidelines Developed for Managing Severe Atopic Dermatitis
Management is generally in a stepwise manner, including moisturizers and avoiding triggers
Mean Cumulative Lifetime Prevalence of Eczema 9.9%
The mean cumulative lifetime prevalence of atopic eczema is 9.9%, according to a research letter.
Upadacitinib Improves Pruritus in Moderate to Severe Atopic Dermatitis
Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.
Dupilumab Beneficial in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
The Phase 3 trial enrolled 251 patients aged 12-17 years old with moderate-to-severe atopic dermatitis, whose disease was not adequately controlled by prescription topical medications or for whom topical treatment was medically inadvisable.
High Patient Burden With Moderate-to-Severe Atopic Dermatitis
Many patients with moderate/severe atopic dermatitis have inadequate disease control
